ArticleJournal of clinical laboratory analysis2019
Predictive value of soluble fms-like tyrosine kinase-1 against placental growth factor for preeclampsia in a Chinese pregnant women population.
Article in Journal of clinical laboratory analysis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.
- Predictive Performance of Placental Protein 13 for Screening Preeclampsia in the First Trimester: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Incremental prognostic value of the fibrinogen-to-albumin ratio for adverse perinatal outcomes in preeclampsia: a dual-center retrospective cohort study.Frontiers in endocrinology · 2026Article
- A dynamic prediction model for preeclampsia using the sFlt-1/PLGF ratio combined with multiple factors.BMC pregnancy and childbirth · 2024Article
- Predictive value of soluble fms-like tyrosine kinase-1 against placental growth factor for preeclampsia in a Chinese pregnant women population.Journal of clinical laboratory analysis · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe purpose of the present study was to explore the predictive effects of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) for preeclampsia.
methodsA total of 1580 singleton pregnant women aged 18-45 years were included in this study. Serum samples were collected and stored frozen during their regular obstetric examinations. A total of 48 women who were eventually diagnosed with preeclampsia among them were defined as the preeclampsia group, other 134 women who were matched with age and sample collecting gestational weeks and finally diagnosed without preeclampsia were selected as control. The concentration of sFlt-1 and PlGF in prestored serum samples was examined. The optimal cut-off of sFlt-1, PlGF, and sFlt-1/PlGF ratio in predicting preeclampsia was determined by establishing the receiver operating characteristic curve (ROC).
resultsSerum PlGF levels in patients with preeclampsia were significantly lower than those in normal pregnancy (P < 0.05), On the contrary, sflt-1 levels and sflt-1/PlGF ratios were significantly higher than those in the normal pregnant women (P < 0.05). The ROC curve study showed that using the sFlt-1/PlGF ratio to predict preeclampsia was better than using PlGF alone but no difference with sFlt-1. When the cut-off of the sFlt-1/PlGF ratio was 26.6, the area under the ROC curve was 0.918, and high sensitivity (85.42%) and specificity (96.27%) for predicting preeclampsia were obtained.
conclusionThe cut-off of sflt-1/PlGF ratio determined by ROC curve has a good predictive value for the occurrence of preeclampsia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.